Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?
- PMID: 20587788
- PMCID: PMC4843793
- DOI: 10.1161/CIRCINTERVENTIONS.109.910638
Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?
Abstract
Background: Previous work on contrast-induced acute kidney injury (CI-AKI) has identified contrast volume as a risk factor and suggested that there is a maximum allowable contrast dose (MACD) above which the risk of CI-AKI is markedly increased. We hypothesized that there is a relationship between contrast volume and CI-AKI and that there might be reason to track incremental contrast volumes above and below the MACD limit.
Methods and results: Consecutive patients undergoing percutaneous coronary intervention (PCI) were prospectively enrolled from 2000 to 2008 (n=10 065). Patients on dialysis before PCI were excluded (n=155). MACD was defined as (5 mL x body weight [kg])/baseline serum creatinine [mg/dL]) and divided into categories in which 1.0 reflects the MACD limit: < or =MACD ratios (<0.5, 0.5 to 0.75, and 0.75 to 1.0) and >MACD (1.0 to 1.5, 1.5 to 2.0, and >2.0). CI-AKI was defined as a > or =0.3 (mg/dL) or > or =50% increase in serum creatinine from baseline or new dialysis. Multivariable regression was conducted to evaluate the effect of exceeding the MACD on CI-AKI. Twenty percent of patients exceeded the MACD. Risk-adjusted CI-AKI increased by an average of 45% for each category exceeding the MACD (odds ratio, 1.45; 95% confidence interval, 1.29 to 1.62) Adjusted odds ratios for each category exceeding the MACD were 1.60 (95% confidence interval, 1.29 to 1.97), 2.02 (95% confidence interval, 1.45 to 2.81), and 2.94 (95% confidence interval, 1.93 to 4.48). CI-AKI for contrast dose <MACD showed no statistical difference (P=0.5).
Conclusions: Contrast volume is a key risk factor for CI-AKI and matters the most in the highest-risk patient. The incremental use of contrast beyond the MACD is associated with an increased risk of CI-AKI.
Figures
Similar articles
-
Revising the Maximal Contrast Dose for Predicting Acute Kidney Injury following Coronary Intervention.Am J Nephrol. 2021;52(4):328-335. doi: 10.1159/000515382. Epub 2021 Apr 7. Am J Nephrol. 2021. PMID: 33827080
-
Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing emergency coronary intervention.Circ J. 2012;76(8):1848-55. doi: 10.1253/circj.cj-11-1248. Epub 2012 May 26. Circ J. 2012. PMID: 22572459 Clinical Trial.
-
Dosing of iodinated contrast volume: a new simple algorithm to stratify the risk of contrast-induced nephropathy in patients with acute coronary syndrome.Catheter Cardiovasc Interv. 2013 Nov 15;82(6):888-97. doi: 10.1002/ccd.24847. Epub 2013 Jul 17. Catheter Cardiovasc Interv. 2013. PMID: 23362013
-
Maximum allowable contrast dose and prevention of acute kidney injury following cardiovascular procedures.Curr Opin Nephrol Hypertens. 2018 Mar;27(2):121-129. doi: 10.1097/MNH.0000000000000389. Curr Opin Nephrol Hypertens. 2018. PMID: 29261551 Free PMC article. Review.
-
Remote Ischemic Conditioning for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Interventions/Coronary Angiography: A Meta-Analysis of Randomized Controlled Trials.J Cardiovasc Pharmacol Ther. 2016 Jan;21(1):53-63. doi: 10.1177/1074248415590197. Epub 2015 Jun 24. J Cardiovasc Pharmacol Ther. 2016. PMID: 26112028 Review.
Cited by
-
A Simple Strategy to Reduce Contrast Media Use and Risk of Contrast-Induced Renal Injury during PCI: Introduction of an "Optimal Contrast Volume Protocol" to Daily Clinical Practice.J Cardiovasc Dev Dis. 2023 Sep 19;10(9):402. doi: 10.3390/jcdd10090402. J Cardiovasc Dev Dis. 2023. PMID: 37754831 Free PMC article.
-
Iodixanol-associated acute kidney injury and prognosis in patients undergoing elective percutaneous coronary intervention: a prospective, multi-center study.Eur Radiol. 2023 Dec;33(12):9444-9454. doi: 10.1007/s00330-023-09964-8. Epub 2023 Jul 22. Eur Radiol. 2023. PMID: 37480548
-
Predictive value of CHA2DS2VASC score for contrast-induced nephropathy after primary percutaneous coronary intervention for patients presenting with acute ST-segment elevation myocardial infarction.Egypt Heart J. 2023 Jun 26;75(1):52. doi: 10.1186/s43044-023-00378-x. Egypt Heart J. 2023. PMID: 37358644 Free PMC article.
-
Halved contrast medium dose in lower limb dual-energy computed tomography angiography-a randomized controlled trial.Eur Radiol. 2023 Sep;33(9):6033-6044. doi: 10.1007/s00330-023-09575-3. Epub 2023 Apr 18. Eur Radiol. 2023. PMID: 37071166 Free PMC article. Clinical Trial.
-
Percutaneous transluminal renal artery stenting using digital subtraction angiography with diluted contrast medium in a patient with severe chronic kidney disease.J Cardiol Cases. 2022 Jul 9;26(5):317-320. doi: 10.1016/j.jccase.2022.06.002. eCollection 2022 Nov. J Cardiol Cases. 2022. PMID: 36312781 Free PMC article.
References
-
- DeFrances CJ, Hall MJ. 2005 National Hospital Discharge Survey. Advance data. 2007:1–19. - PubMed
-
- Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA. Pathophysiology of contrast-induced nephropathy. The American journal of cardiology. 2006;98:14K–20K. - PubMed
-
- Brown JR, Malenka DJ, DeVries JT, Robb JF, Jayne JE, Friedman BJ, Hettleman BD, Niles NW, Kaplan AV, Schoolwerth AC, Thompson CA. Transient and persistent renal dysfunction are predictors of survival after percutaneous coronary intervention: insights from the Dartmouth Dynamic Registry. Catheter Cardiovasc Interv. 2008;72:347–354. - PMC - PubMed
-
- McCullough PA. Acute kidney injury with iodinated contrast. Critical care medicine. 2008;36:S204–S211. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
